THE PHAGE develops AI to predict post-meal blood glucose levels and provide personalized health recommendations.
THE PHAGE has raised $3.6M in total funding. The most recent round was Series A. The last funding was announced in October 2026.
THE PHAGE's investors include Mizuho Capital, Genesia Ventures, ITOCHU Technology Ventures, KSP, Shoko Chukin Bank.
THE PHAGE is headquartered in Shibuya, Japan.
THE PHAGE develops AI to predict post-meal blood glucose levels and provide personalized health recommendations.
THE PHAGE is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"THE PHAGE — Funding & Investors." VCBacked, October 9, 2026, https://www.vcbacked.co/company/the-phage. Accessed November 1, 2026.
VCBacked. (2026). THE PHAGE — Funding & Investors. Retrieved November 1, 2026, from https://www.vcbacked.co/company/the-phage
{{cite web |title=THE PHAGE — Funding & Investors |url=https://www.vcbacked.co/company/the-phage |website=VCBacked |access-date=November 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated